Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis  

作　　者：Yunqing Liu Dejun Yan Lin Yang Xian Chen Chun Hu Meilan Chen 

机构地区：[1]Key Laboratory of Brain,Cognition and Education Sciences,South China Normal University,Ministry of Education,Guangzhou,China [2]Institute for Brain Research and Rehabilitation,South China Normal University,Guangzhou 510631,China [3]Guangdong Second Provincial General Hospital,Guangzhou 510317,China [4]Department of Anesthesiology,the Affiliated Panyu Central Hospital of Guangzhou Medical University,Guangzhou,China [5]Rehabilitation Medicine Institute of Panyu District,Guangzhou 511499,China

出　　处：《Translational Neurodegeneration》2024年第1期833-836,共4页转化神经变性病(英文)

基　　金：supported by grants from Guangdong Basic and Applied Basic Research Foundation(2023A1515010477);the National Natural Science Foundation of China(32000690);the Key-Area Research and Development Program of Guangdong Province,China(2019B030335001);the Key Medical and Health Projects of Panyu District Science and Technology Plan,Guangzhou,China(2023-Z04-103).

摘　　要：Main text Amyotrophic lateral sclerosis(ALS)is a neurodegenera-tive disease characterized by the selective loss of motor neurons(MNs),resulting in progressive disability and mortality with a rapid course.Current approaches such as multidisciplinary care,disease-modifying therapies,pulmonary intervention,and dietary and nutritional intervention can only slow ALS progression[1].It is imperative to dissect the underlying mechanisms and explore novel treatment targets.

关 键 词：MORTALITY STATHMIN TREATMENT 

分 类 号：R74[医药卫生—神经病学与精神病学]